Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um ensaio clínico de injeção de BAT4406F em pacientes com distúrbios do espectro da neuromielite óptica

29 de setembro de 2026 atualizado por: Bio-Thera Solutions

Um estudo de fase II/III para avaliar a eficácia e segurança da injeção de BAT4406F em pacientes com doença da linhagem neuromielite óptica

This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .

Visão geral do estudo

Descrição detalhada

This study was a phase II/III multicenter, randomized, double-blind, placebo-controlled study, which was divided into screening period (4 weeks) , randomized control period (RCP) , and open-label period (Olp)A total of 162 subjects were enrolled during the screening period and randomly assigned 2:1 to either the BAT4406F group or the placebo group after randomization on Day 1 of the RCP, subjects would receive BAT4406F (at a dose of 500mg) or placebo, intravenously, at D 1 and D 182, respectively.

If any of the following conditions occur, subjects can enter OLP from RCP: 1. Subjects who complete the 52-week RCP study without recurrence of NMOSD can enter Olp within 14 days after the end of the RCP study. 2. In the stage of RCP, NMOSD recurred. After rescue therapy, the patients with stable condition could enter OLP within 28 days after diagnosis. Subjects continued to participate in the RCP study if they were not identified by CEC as having a relapse upon examination. 3. When a protocol-defined first relapse event of 35 cases is observed, or when all 162 subjects have completed randomization and 12 months have elapsed since the first dose in the last of these subjects, or when recommended by the Independent Data Monitoring Committee (IDMC) , the RCP study should be stopped for enrolled subjects, and all enrolled subjects at the RCP stage should stop the RCP study within 14 days of entry into OLP, after which subjects will receive BAT4406F injection at the same dose as RCP, at d 1 of OLP. After termination of the RCP study with BAT4406F every 6 months, subjects were given the option of enrolling in the OLP study.

Tipo de estudo

Intervencional

Inscrição (Estimado)

162

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Baotou, China
        • The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
      • Beijing, China
        • Beijing Hospital
      • Beijing, China
        • China-japan friendship Hospital
      • Beijing, China
        • The first hospital of Peking University
      • Changsha, China
        • The Central South University Xiang Ya Hospital
      • Changsha, China
        • Xiangya 2nd hospital of central south university
      • Chongqing, China
        • First affiliated hospital of chongqing medical university
      • Dalian, China
        • The first affiliated hospital of Dalian Medical University
      • Fuzhou, China
        • First affiliated hospital of fujian medical university
      • Guangzhou, China
        • The first hospital affiliated to sun yat-sen university
      • Guangzhou, China
        • The third hospital affiliated to sun yat-sen university
      • Guangzhou, China
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      • Guangzhou, China
        • The first People's Hospital of Guangzhou
      • Hangzhou, China
        • People's Hospital of Zhejiang province
      • Hefei, China
        • Anhui Provincial Hospital
      • Hefei, China
        • Second Affiliated Hospital of Anhui Medical University
      • Jinan, China
        • Shandong University Qilu Hospital
      • Jingzhou, China
        • Jingzhou Central Hospital
      • Kunming, China
        • First Affiliated Hospital of the Kunming Medical University
      • Nanchang, China
        • Second Affiliated Hospital of Nanchang University
      • Nanchong, China
        • Affiliated Hospital of North Sichuan Medical College
      • Nanjing, China
        • Drum Tower Hospital affiliated to Medical College of Nanjing University
      • Nanjing, China
        • The Chinese people's liberation army general hospital in eastern theater
      • Nanjing, China
        • Southeast university affiliated zhongda hospital
      • Nantong, China
        • The first People's Hospital of Nantong
      • Qingdao, China
        • Qingdao municipal hospital
      • Shanghai, China
        • Mount Hua Hospital affiliated to Fudan University
      • Shanghai, China
        • Shuguang hospital affiliated to Shanghai University of Traditional Chinese medicine
      • Shanghai, China
        • Zhongshan hospital affiliated to Fudan University
      • Shenzhen, China
        • Shenzhen city people's hospital
      • Shijia Zhuang, China
        • Second Hebei Medical University Hospital
      • Shijiazhuang, China
        • The Third Hospital of Hebei Medical University
      • Suzhou, China
        • The Second Affiliated Hospital of Suzhou University
      • Suzhou, China
        • First Affiliated Hospital of Suzhou University
      • Taiyuan, China
        • The first hospital of shanxi medical university
      • Tianjin, China
        • Tianjin Medical University General Hospital
      • Wenzhou, China
        • The first hospital affiliated to wenzhou medical college
      • Wuhan, China
        • Tongji hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuhan, China
        • Xiehe hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuxi, China
        • Wuxi city people's hospital
      • Xi'an, China
        • Second Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
      • Xi'an, China
        • Xi'an high-tech Hospital Co. , Ltd.
      • Xianyang, China
        • Yan 'an University Xianyang Hospital Co. , Ltd.
      • Zhengzhou, China
        • Henan province people's hospital
      • Zhenzhou, China
        • Zhengzhou university first affiliated hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Age greater than or equal to the age of 18 and less than or equal to 65 patients, gender not limited;
  2. Met the 2015 international NMO diagnostic panel (IPND) criteria for NMOSD, And AQP4-IGG positive patients
  3. Screening before 2 times at least 2 years experience with clinical records of relapse,or experienced at least 1 clinically documented recurrence within 1 year prior to screening
  4. For subjects who had a relapse before screening, symptoms needed to be stable for at least 4 weeks before randomization
  5. Into the group of former dosage of corticosteroids under 30 mg and prednisone equivalent,and the trial drug must be used within a month after the withdrawal of hormones
  6. The score of EDSS 7 or less
  7. Has the fertility of men and women must agree during treatment and 6 months after the last dose of using effective birth control method;
  8. Agreed to participate in trials, and books to sign the informed consent

Exclusion Criteria:

  1. CD19 + b-cell count below the lower limit of normal, b-cell-scavenger drugs used 6 months before baseline or within 5 half-lives of the drug, whichever is older (including but not limited to Rituximab, enalizumab, etc.) ;

  2. 6 months prior to the baseline used other monoclonal antibody therapy;Baseline used within five half-life before other biological preparation;

  3. Used it for 3 months prior to the baseline McCaw phenol ester, azathioprine and methotrexate;6 months prior to the baseline using cyclophosphamide;Baseline before five half-life

  4. Within a month before the filter used intravenous immunoglobulin (IVIG), plasma exchange (PE);

  5. Within 4 weeks before screening received vaccine or live attenuated;Within 2 weeks before the baseline received inactivated vaccine;Baseline received within 4 weeks before the new coronavirus vaccine

  6. In another clinical study and the baseline from the test drug treatment under three months or 5 half-life of the drug (the long time limit shall prevail);

  7. This test for monoclonal antibody has a history of allergies, known in drug allergy patients;Serious drug allergy or for two or over two kinds of food or drugs;

  8. 6 months prior to screening, except NMOSD need continuous oral or intravenous glucocorticoid dose > 20 mg/day of any more than 21 days

  9. Abnormal liver, kidney and bone marrow reserve

  10. HIV positive at HIV history or enrollment screening; History of hepatitis B Andor hepatitis C or Hepatitis B surface antigen (HBSAG) positivity at screening [ or Hepatitis B core antibody positive, hepatitis B surface antibody negative, Hepatitis B virus deoxynucleotides (HBV DNA) quantification exceeding normal range ] ; Or Hepatitis C virus (HCV) antibody positive [ with HCV-rna quantitation exceeding the normal range ] , Treponema pallidum antibody positive at the time of enrollment;

  11. Comply with any of the following subjects a latent or active TB infection related standards:

    1. Current or past people with active TB;
    2. In history and/or physical examination during filter tip physical signs or symptoms of active TB;
    3. Recent close contact with people with active TB;
    4. At the time of screening, the positive result of TB infected T cells was found. A test could be repeated if the subject's first tb-infected t-cell test result was inconclusive, and the patient was excluded from this study if the test result was inconclusive (or positive) again.
  12. Covid-19 infection was diagnosed with clinical symptoms or signs consistent with 2019 coronavirus (COVID-19) infection (eg, fever, dry cough, dyspnea, sore throat, and fatigue) within 4 weeks before screening or during screening, or upon appropriate laboratory testing (at the discretion of the investigator or in accordance with local regulations) . If COVID-19 infection is confirmed before screening, appropriate laboratory testing is required to confirm that the infection has been cured;

  13. Suffering from metabolic, hematological, renal, hepatic, pulmonary, neuroendocrine, cardiac, infectious, gastrointestinal or other autoimmune diseases, the researchers believe there is an unacceptable risk to patients, or it may affect NMOSD assessment;

  14. According to the researchers, there was a history of drug and alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 125 mL of wine) in the 12 months before screening;

  15. Subjects who are unable to undergo an MRI scan (for example, are allergic to Gd-containing MRI contrast media, have a pacemaker, defibrillator, or other metallic object with internal or external limitations to performing an MRI scan) ;

  16. Pregnant or lactating women, and screening or baseline pregnancy test positive female subjects;

  17. Researchers think that the other does not fit to participate in this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Experimental group:BAT4406F

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

Comparador Ativo: Control group:BAT4406F Placebos

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Pharmacodynamics
Prazo: RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years

The follow-up time point of peripheral blood before and after the analysis to the medicine CD19 + B lymphocytes proportion/count change

RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years
Pharmacodynamics
Prazo: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

Serum immunoglobulin (IgG and IgM) levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacodynamics
Prazo: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

AQP4-IgG levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacokinetics(PK)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Tmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmin

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

AUC0-tau

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

t1/2

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

CL

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Vd

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Immunogenicity evaluation
Prazo: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Resistant antibody positive rate (ADA)

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years
Immunogenicity evaluation
Prazo: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

The titers of Ada positive samples

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Vital signs
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal vital signs

Through study completion,up to 49 months. And OLP maximum period for 3 years.
physical examination
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal physical examination findings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Laboratory tests
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal laboratory test results

Through study completion,up to 49 months. And OLP maximum period for 3 years.
electrocardiogram( ECG )
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal ECG readings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Adverse events(AE)
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Adverse events (AE) is happening, is happening because of adverse events leading to withdrawal Adverse events associated with drugs The occurrence of Serious adverse events (SAE)

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Injection site reactions
Prazo: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with injection site reactions

Through study completion,up to 49 months. And OLP maximum period for 3 years.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Xiangjun Chen, Doctor, Huashan Hospital
  • Investigador principal: Chunfeng Liu, Doctor, Second Affiliated Hospital of Suzhou University
  • Investigador principal: Qun Xue, Doctor, First Affiliated Hospital of Suzhou University
  • Investigador principal: Yan Jiang, Doctor, Anhui Provincial Hospital
  • Investigador principal: Yuying Zhao, Doctor, Shandong University Qilu Hospital
  • Investigador principal: Li Guo, Doctor, Second Hebei Medical University Hospital
  • Investigador principal: Meini Zhang, Doctor, The First Affiliated Hospital of Shanxi Medical University
  • Investigador principal: Huan Yang, Doctor, The Central South University Xiang Ya Hospital
  • Investigador principal: Daishi Tian, Doctor, Tongji hospital affiliated to Tongji Medical College
  • Investigador principal: Yuming Xu, Doctor, The First Affiliated Hospital of Zhengzhou University
  • Investigador principal: Jianglong Tu, Doctor, Second Affiliated Hospital of Nanchang University
  • Investigador principal: Wei Qiu, Doctor, The third hospital affiliated to sun yat-sen university
  • Investigador principal: Honghao Wang, Doctor, The First People's Hospital of Guangzhou
  • Investigador principal: Xiaoling Luo, Doctor, Shenzhen city people's hospital
  • Investigador principal: Aiyu Lin, Doctor, First Affiliated Hospital of Fujian Medical University
  • Investigador principal: Chunming Xie, Doctor, China University Hospital of Southeast University
  • Investigador principal: Xiang Li, Doctor, The first hospital affiliated to wenzhou medical college
  • Investigador principal: Lan Tan, Doctor, Qingdao City Hospital
  • Investigador principal: Fudong Shi, Doctor, Tianjin Medical University General Hospital
  • Investigador principal: Jiewen Zhang, Doctor, Henan Provincial People's Hospital
  • Investigador principal: Jing Ding, Doctor, Shanghai Zhongshan Hospital
  • Investigador principal: Ping Chen, Doctor, Xianyang yanan university hospital co., LTD
  • Investigador principal: Zunbo Li, Doctor, Xi'an high-tech Hospital Co. , Ltd.
  • Investigador principal: Qihe Dai, Doctor, Jingzhou city central hospital
  • Investigador principal: Dan Liu, Doctor, the first hospital of Baotou medicine college
  • Investigador principal: Junyan Liu, Doctor, Hebei Medical University Third Hospital
  • Investigador principal: Yiqi Wang, Doctor, Zhejiang Province People's Hospital
  • Investigador principal: Bo Hu, Doctor, Xiehe hospital affiliated to tongji medical college
  • Investigador principal: Yanbing Han, Doctor, First Affiliated Hospital of the Kunming Medical University
  • Investigador principal: Feng Wang, Doctor, Wuxi city people's hospital
  • Investigador principal: Zhanhua Liang, Doctor, The First Affiliated Hospital of Dalian Medical University
  • Investigador principal: Weihe Zhang, Doctor, Sino-Japanese Friendship Hospital
  • Investigador principal: Xiangyang Zhu, Doctor, Nantong First People's Hospital
  • Investigador principal: Xinfeng Liu, Doctor, The Chinese people's liberation army general hospital in eastern theater
  • Investigador principal: Weidong Pan, Doctor, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  • Investigador principal: Wei Lu, Doctor, The Central South University Xiang YA II hospital
  • Investigador principal: Huiyu Feng, Doctor, The first hospital affiliated to sun yat-sen university
  • Investigador principal: Yamei Tang, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Investigador principal: Juming Yu, Doctor, Affiliated Hospital of North Sichuan Medical College
  • Investigador principal: Jun Guo, Doctor, The Second Affiliated Hospital of the PLA Air Force Military Medical University
  • Investigador principal: Yanghua Tian, Doctor, The Second Hospital of Anhui Medical University
  • Investigador principal: Feng Gao, Doctor, The first hospital of Peking University
  • Investigador principal: Yun Xu, Doctor, Drum tower hospital affiliated to nanjing university school of medicine

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de agosto de 2023

Conclusão Primária (Estimado)

31 de dezembro de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

31 de julho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de setembro de 2023

Primeira postagem (Real)

21 de setembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • BAT-4406F-002-CR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever